Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

John Byrd, MD, Discusses Acalabrutinib vs Ibrutinib for Patients With CLL

06/09/2021

Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.

Dr Byrd shares results from a...

06/09/2021

Oncology

Videos

Combo Therapy Demonstrates Durable Responses in Patients With CLL

06/07/2021

Paolo Ghia, MD, PhD, discusses the CAPTIVATE study of ibrutinib plus venetoclax in patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.

Paolo Ghia, MD, PhD, discusses...

06/07/2021

Oncology

Videos

Ibrutinib Therapy Demonstrates Sustained PFS, OS in Patients With CLL/SLL

06/04/2021

Paul Barr, MD, shares findings from the RESONATE-2 study of ibrutinib in patients with CLL/SLL. These data are being presented at the 2021 ASCO Annual Meeting.

Paul Barr, MD, shares findings...

06/04/2021

Oncology

Conference Insider

Cirmtuzumab, Ibrutinib Therapy Well Tolerated in CLL/MCL

06/02/2021

Cirmtuzumab in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies.

Cirmtuzumab in combination with...

06/02/2021

Oncology

Conference Insider

Increased Risk for HZ Varies by Age, Treatment in Patients With CLL

05/28/2021

According to study findings presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.

According to study findings...

05/28/2021

Oncology